Skip to main content
Top
Published in: Endocrine 2/2011

01-04-2011 | Original Article

Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population

Authors: Jaeseong Jo, Ji Eun Yun, Heeyeon Lee, Heejin Kimm, Sun Ha Jee

Published in: Endocrine | Issue 2/2011

Login to get access

Abstract

Total bilirubin, not direct or indirect bilirubin, has been reported to associate inversely with metabolic syndrome. Therefore, we aimed to evaluate the association between bilirubin subtypes and metabolic syndrome among the Korean population. This study included 5,231 Koreans (3,008 men, 2,223 women) aged 30–87 years, who visited the Health promotion centers in Seoul from April, 2006 to June, 2007. The associations of direct, indirect, and total bilirubin classified in quartiles with metabolic syndrome were measured by logistic regression analyses in men and women. Odds ratios (95% confidence intervals) of the lowest, 2nd and 3rd quartiles of direct serum bilirubin compared with the highest quartile (reference) were 2.3 (1.6–3.2), 1.8 (1.3–2.4), and 1.8 (1.4–2.4) among men, and 5.5 (2.6–11.5), 3.1 (1.5–6.7), and 1.9 (0.9–4.3) among women, respectively. In a multivariable adjusted model, however, the significance of inverse associations with total and indirect bilirubin became attenuated. The relation was consistent particularly with direct bilirubin in subgroups of metabolic syndrome components such as central obesity, hypertriglyceridemia, hyperglycemia, and low HDL-cholesterol in both men and women. Of the three subtypes of serum bilirubin, the inverse association of metabolic syndrome was significantly apparent and consistent with direct bilirubin.
Literature
1.
go back to reference R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, B.N. Ames, Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046 (1987)PubMedCrossRef R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, B.N. Ames, Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046 (1987)PubMedCrossRef
2.
go back to reference T.W. Wu, J. Wu, R.K. Li, D. Mickle, D. Carey, Albumin-bound bilirubins protect hyman ventricular myocytes against oxyradical damage. Biochem. Cell Biol. 69, 683–688 (1991)PubMedCrossRef T.W. Wu, J. Wu, R.K. Li, D. Mickle, D. Carey, Albumin-bound bilirubins protect hyman ventricular myocytes against oxyradical damage. Biochem. Cell Biol. 69, 683–688 (1991)PubMedCrossRef
3.
go back to reference H.A. Schwertner, L. Vitek, Gilbert syndrome, UGT1A1*28 allel, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198, 1–11 (2008)PubMedCrossRef H.A. Schwertner, L. Vitek, Gilbert syndrome, UGT1A1*28 allel, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198, 1–11 (2008)PubMedCrossRef
4.
go back to reference S.C. Hunt, F. Kronenberg, J.H. Eckfeldt, P.N. Hopkins, R.H. Myers, G. Heiss, Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154, 747–754 (2001)PubMedCrossRef S.C. Hunt, F. Kronenberg, J.H. Eckfeldt, P.N. Hopkins, R.H. Myers, G. Heiss, Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154, 747–754 (2001)PubMedCrossRef
5.
go back to reference B. Krijgsman, J.A. Papadkis, E.S. Ganotakis, D.P. Mikhailidis, G. Hamilton, The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int. Angiol. 21, 44–52 (2002)PubMed B. Krijgsman, J.A. Papadkis, E.S. Ganotakis, D.P. Mikhailidis, G. Hamilton, The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int. Angiol. 21, 44–52 (2002)PubMed
6.
go back to reference D. Erdogan, H. Gullu, E. Yildirim, D. Tok, O. Ciftci, S.T. Baycan, H. Muderrisoglu, Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431–437 (2006)PubMedCrossRef D. Erdogan, H. Gullu, E. Yildirim, D. Tok, O. Ciftci, S.T. Baycan, H. Muderrisoglu, Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431–437 (2006)PubMedCrossRef
7.
go back to reference H.J. Kimm, J.E. Yun, J. Jo, S.H. Jee, Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 40, 3422–3427 (2009)PubMedCrossRef H.J. Kimm, J.E. Yun, J. Jo, S.H. Jee, Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 40, 3422–3427 (2009)PubMedCrossRef
8.
go back to reference E.S. Ford, A.H. Mokdad, W.H. Giles, D.W. Brown, The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352 (2003)PubMedCrossRef E.S. Ford, A.H. Mokdad, W.H. Giles, D.W. Brown, The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352 (2003)PubMedCrossRef
9.
go back to reference P.M. Gorter, J.K. Olijhoek, Y. van der Graaf, A. Algra, T.J. Rabelink, F.L. Visseren, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173, 363–369 (2004)PubMedCrossRef P.M. Gorter, J.K. Olijhoek, Y. van der Graaf, A. Algra, T.J. Rabelink, F.L. Visseren, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173, 363–369 (2004)PubMedCrossRef
10.
go back to reference M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D’Agostino, P.W. Wilson, C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380–385 (2004)PubMedCrossRef M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D’Agostino, P.W. Wilson, C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380–385 (2004)PubMedCrossRef
11.
go back to reference J.S. Torgerson, A.K. Lindroos, C.D. Sjostrom, R. Olsson, L. Lissner, L. Sjostrom, Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes. Res. 5, 105–114 (1997)PubMed J.S. Torgerson, A.K. Lindroos, C.D. Sjostrom, R. Olsson, L. Lissner, L. Sjostrom, Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes. Res. 5, 105–114 (1997)PubMed
12.
go back to reference L.Y. Lin, H.K. Kuo, J.J. Hwang, L.P. Lai, F.T. Chiang, C.D. Tseng, J.L. Lin, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203, 563–568 (2009)PubMedCrossRef L.Y. Lin, H.K. Kuo, J.J. Hwang, L.P. Lai, F.T. Chiang, C.D. Tseng, J.L. Lin, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203, 563–568 (2009)PubMedCrossRef
13.
go back to reference L.H. Bremier, K.A. Spyropolous, A.F. Winder, D.P. Mikhailidis, G. Hamilton, Is bilirubin protective against coronary artery disease? Clin. Chem. 40, 1987–1988 (1994) L.H. Bremier, K.A. Spyropolous, A.F. Winder, D.P. Mikhailidis, G. Hamilton, Is bilirubin protective against coronary artery disease? Clin. Chem. 40, 1987–1988 (1994)
14.
go back to reference L.H. Bremier, G. Wannamethee, S. Ebrahim, A.G. Shaper, Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504–1508 (1995) L.H. Bremier, G. Wannamethee, S. Ebrahim, A.G. Shaper, Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504–1508 (1995)
15.
go back to reference H.A. Schwertner, W.G. Jackson, G. Tolan, Association of Low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18–23 (1994)PubMed H.A. Schwertner, W.G. Jackson, G. Tolan, Association of Low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18–23 (1994)PubMed
16.
go back to reference S. Pineda, O.Y. Bang, J.L. Saver, S. Starkman, S.W. Yun, D.S. Liebeskind, L.K. Ali, S.H. Shah, B. Ovbiagele, Association of serum bilirubin with ischemic stroke outcomes. J. Stroke Cerebrovasc. Dis. 17, 147–152 (2008)PubMedCrossRef S. Pineda, O.Y. Bang, J.L. Saver, S. Starkman, S.W. Yun, D.S. Liebeskind, L.K. Ali, S.H. Shah, B. Ovbiagele, Association of serum bilirubin with ischemic stroke outcomes. J. Stroke Cerebrovasc. Dis. 17, 147–152 (2008)PubMedCrossRef
17.
go back to reference H.J. Hwang, S.H. Kim, Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin. Chim. Acta 411, 1496–1501 (2010)PubMedCrossRef H.J. Hwang, S.H. Kim, Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin. Chim. Acta 411, 1496–1501 (2010)PubMedCrossRef
18.
go back to reference T. Nakagami, K. Toyomura, T. Kinoshita, S. Morisawa, A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim. Biophys. Acta 1158, 189–193 (1993)PubMed T. Nakagami, K. Toyomura, T. Kinoshita, S. Morisawa, A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim. Biophys. Acta 1158, 189–193 (1993)PubMed
19.
go back to reference M. Mamtani, A. Patel, R. Renge, H. Kulkarni, Prognostic value of direct bilirubin in neonatal hyperbilirubinemia. Indian J. Pediatr. 74, 819–822 (2007)PubMedCrossRef M. Mamtani, A. Patel, R. Renge, H. Kulkarni, Prognostic value of direct bilirubin in neonatal hyperbilirubinemia. Indian J. Pediatr. 74, 819–822 (2007)PubMedCrossRef
20.
go back to reference S. Shiomi, D. Habu, T. Kuroki, S. Ishida, N. Tatsumi, Clinical usefulness of conjugated bilirubin levels in patients with acute liver diseases. J. Gastroenterol. 34, 88–93 (1993)CrossRef S. Shiomi, D. Habu, T. Kuroki, S. Ishida, N. Tatsumi, Clinical usefulness of conjugated bilirubin levels in patients with acute liver diseases. J. Gastroenterol. 34, 88–93 (1993)CrossRef
21.
go back to reference B. Li, Z. Wang, J.J. Fang, C.Y. Xu, W.X. Chen, Evaluation of prognostic markers in severe drug-induced liver disease. World J. Gastroenterol. 13, 628–632 (2007)PubMed B. Li, Z. Wang, J.J. Fang, C.Y. Xu, W.X. Chen, Evaluation of prognostic markers in severe drug-induced liver disease. World J. Gastroenterol. 13, 628–632 (2007)PubMed
22.
go back to reference O. Yavuz, S. Aras, Interaction between serum bilirubin level and lipid profile. T Klin. Tip Bilim. 22, 276–280 (2002) O. Yavuz, S. Aras, Interaction between serum bilirubin level and lipid profile. T Klin. Tip Bilim. 22, 276–280 (2002)
23.
go back to reference R.J. Simon Maxwell, Y.H. Gregory, Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. 44, 307–317 (1997)CrossRef R.J. Simon Maxwell, Y.H. Gregory, Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. 44, 307–317 (1997)CrossRef
24.
go back to reference T.W. Wu, K.P. Fung, C.C. Yang, Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54, 477–481 (1994) T.W. Wu, K.P. Fung, C.C. Yang, Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54, 477–481 (1994)
25.
go back to reference J. Neuzil, R. Stocker, Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 269, 16712–16719 (1994)PubMed J. Neuzil, R. Stocker, Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 269, 16712–16719 (1994)PubMed
26.
go back to reference T. Yamaguchi, F. Horio, T. Hashizume, M. Ttanaka, S. Ikeda, A. Kakinuma, H. Nakajima, Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem. Biophys. Res. Commun. 4, 11–19 (1995)CrossRef T. Yamaguchi, F. Horio, T. Hashizume, M. Ttanaka, S. Ikeda, A. Kakinuma, H. Nakajima, Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem. Biophys. Res. Commun. 4, 11–19 (1995)CrossRef
27.
go back to reference T. Aizawa, N. Ishizaka, J. Taguchi, S. Kimura, K. Kurokawa, M. Ohno, Baloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injury rat carotid artery. Biochem. Biophys. Res. Commun. 261, 302–307 (1999)PubMedCrossRef T. Aizawa, N. Ishizaka, J. Taguchi, S. Kimura, K. Kurokawa, M. Ohno, Baloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injury rat carotid artery. Biochem. Biophys. Res. Commun. 261, 302–307 (1999)PubMedCrossRef
28.
go back to reference B. Frei, R. Stocker, B.N. Ames, Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 85, 9748–9752 (1988)PubMedCrossRef B. Frei, R. Stocker, B.N. Ames, Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 85, 9748–9752 (1988)PubMedCrossRef
29.
go back to reference C. Hammerman, R. Goldstein, M. Kaplan, M. Eran, D. Goldschmidt, A.I. Eidelman, L.M. Gartner, Bilirubin in the premature: toxic waste or natural defense? Clin. Chem. 44, 2551–2553 (1998)PubMed C. Hammerman, R. Goldstein, M. Kaplan, M. Eran, D. Goldschmidt, A.I. Eidelman, L.M. Gartner, Bilirubin in the premature: toxic waste or natural defense? Clin. Chem. 44, 2551–2553 (1998)PubMed
30.
go back to reference F. Armutcu, M. Ataymen, H. Atmaca, A. Gurel, Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 46, 785–790 (2008)PubMedCrossRef F. Armutcu, M. Ataymen, H. Atmaca, A. Gurel, Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 46, 785–790 (2008)PubMedCrossRef
31.
go back to reference B. Burchell, R. Hume, Molecular genetic basis of Gilbert’s syndrome. J. Gastroenterol. Hepatol. 14, 960–966 (1999)PubMedCrossRef B. Burchell, R. Hume, Molecular genetic basis of Gilbert’s syndrome. J. Gastroenterol. Hepatol. 14, 960–966 (1999)PubMedCrossRef
32.
go back to reference S.J. Yoon, H.S. Lee, S.W. Lee, J.E. Yun, S.Y. Kim, E.R. Cho, S.J. Lee, E.J. Jee, H.Y. Lee, J. Park, H.S. Kim, S.H. Jee, The association between adiponectin and diabetes in the Korean population. Metabolism 57, 853–857 (2008)PubMedCrossRef S.J. Yoon, H.S. Lee, S.W. Lee, J.E. Yun, S.Y. Kim, E.R. Cho, S.J. Lee, E.J. Jee, H.Y. Lee, J. Park, H.S. Kim, S.H. Jee, The association between adiponectin and diabetes in the Korean population. Metabolism 57, 853–857 (2008)PubMedCrossRef
33.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001)
34.
go back to reference S. Inoue, P. Zimmet, I. Caterson, C. Chunming, Y. Ikeda, A.K. Khalid, Y.S. Kim, J. Bassett, The Asia-Pacific perspective: redefining obesity and its treatment. International Obesity Task Force. Western Pacific Region of the World Health Organization (2000) S. Inoue, P. Zimmet, I. Caterson, C. Chunming, Y. Ikeda, A.K. Khalid, Y.S. Kim, J. Bassett, The Asia-Pacific perspective: redefining obesity and its treatment. International Obesity Task Force. Western Pacific Region of the World Health Organization (2000)
Metadata
Title
Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population
Authors
Jaeseong Jo
Ji Eun Yun
Heeyeon Lee
Heejin Kimm
Sun Ha Jee
Publication date
01-04-2011
Publisher
Springer US
Published in
Endocrine / Issue 2/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9417-2

Other articles of this Issue 2/2011

Endocrine 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.